Mannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7
MannKind Corporation (Nasdaq: MNKD) is set to showcase its innovative diabetes solutions at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans from June 3-7, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MannKind Corporation (Nasdaq: MNKD) is set to showcase its innovative diabetes solutions at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans from June 3-7, 2022. Highlighting its commitment to diabetes care, the company will feature products like Afrezza® and V-Go®. MannKind will host a booth (#1019) to engage healthcare professionals and present an abstract on Technosphere® Insulin. Additionally, a Product Theater event on ultra-rapid inhaled insulin will take place on June 4 at 4:30 p.m. (ET) with featured experts.
Details
News Market Reaction – MNKD
The recorded move for MNKD in the trading session of this news was +11.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, will showcase its mealtime insulin solutions and expanding efforts within the diabetes community at the American Diabetes Association’s 82nd Scientific Sessions, June 3-7 in New Orleans.
“MannKind is committed to providing products that address unmet needs for patients living with diabetes,” said Alejandro Galindo, Executive Vice President, Endocrine Business Unit for MannKind Corporation. “This effort is demonstrated by our growing portfolio of products, including Afrezza® and V-Go®, that change the way diabetes is managed.”
When the exhibit hall opens at ADA, MannKind will host a booth (Booth #1019) to share information about its expanding diabetes products, host meetings with health care professionals (HCPs). MannKind will also publish an abstract on “Augmenting Clinical Trial Data within Silico Evidence to Evaluate Initial Conversion Dose Changes for Technosphere® Insulin (TI).” The abstract will be published in category 12-E Clinical Therapeutics/New Technology – Insulins.
MannKind will present a Product Theater event (product theater #3) on Saturday, June 4 at 4:30 p.m. (ET) discussing “Ultra Rapid-Acting Inhaled Insulin for Diabetes Management.” Dr. Kevin Kaiserman, Vice President, Medical Affairs & Safety, Endocrine Business Unit for MannKind Corporation, will be joined by Dr. Steven Edelman and Dr. Jeremy Pettus of Taking Control Of Your Diabetes (TCOYD) to speak during the program.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of convenient and therapeutic products for patients with endocrine and orphan lung diseases. MannKind was established in 1991, and is located in Danbury, Conn., Marlborough, Mass., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more and follow us on LinkedIn, Facebook, Twitter or Instagram.
AFREZZA, MANNKIND, TECHNOSPHERE, V-GO and the MannKind logo are registered trademarks of MannKind Corporation.
MANNKIND CONTACTS:
Christie Iacangelo, Corporate Communications
(818) 292-3500
Email: media@mannkindcorp.com
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.